REFRACTORY MERKEL CELL CARCINOMA
Clinical trials for REFRACTORY MERKEL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MERKEL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MERKEL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo tested for Tough-to-Treat skin cancer
Disease control OngoingThis study is for people with advanced Merkel cell carcinoma, a rare and aggressive skin cancer, that has worsened despite prior immunotherapy. It is testing whether a new oral drug called tuvusertib, which targets cancer cell DNA repair, works better alone or when combined with …
Matched conditions: REFRACTORY MERKEL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Virus + drug combo tested for Tough-to-Treat skin cancers
Disease control OngoingThis study is testing a two-part treatment for patients with advanced skin cancers or rare lymphomas that have not responded to other therapies. First, a modified virus is injected directly into tumors to help the immune system recognize cancer. Then, an immunotherapy drug is giv…
Matched conditions: REFRACTORY MERKEL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC